8:00 am Registration & Morning Coffee

8:30 am Chair’s Opening Remarks

8:45 am Opening Keynote: Unity Biotechnologies’ Pipeline Progression: From Mice Models to First-in-Human Trials

9:01 am
Innovative Therapeutic Approaches Targeting Age-Related Diseases

9:10 am Targeting the Biology of Aging to Prevent or Treat Aging-Related

9:35 am Future of longevity industry and Announcement of rejuvenation results by Gero.AI

Synopsis

• Gero is developing drugs against aging and aging-related diseases using nextgeneration
AI technology.
• Gero targets fundamental aging mechanisms, and other aging-related conditions
such as neurodegeneration and accelerated aging/frailty after chemotherapy.
• Gero managed to overcome limitations of the previous-generation AI by offering
not just a correlation analysis of biological big data, but causative models built
with the use of physics of complex dynamic systems in addition to advanced
machine learning.
• The platform is successfully validated, enabling life extension and rejuvenation of
multiple species. The Gero approach triggered multiple collaborations and publications
with the world’s top academics, including researchers from Harvard Medical School,
MIT, NUS, Roswell Park Comprehensive Cancer Center. Gero is one investment round
away from getting a proof of concept in humans. Previous round investors are pharma
professionals and AI entrepreneurs with exits to Facebook and Google

9:45 am Panel Discussion on Outsourcing Requirements from Biotech and Pharma in the Longevity Therapeutics Space

10:20 am Speed Networking

10:45 am Morning Refreshments

Innovative Therapeutic Approaches Targeting Age-Related Diseases – Part 1

11:15 am Drugging mTORC1, Shc & Mitochondria to Increase Functional Longevity

  • Gino Cortopassi Professor, Molecular Biosciences, University of California Davis

11:40 am Rejuvenating Aged Tissues by Harnessing the Regenerative Secretome of Pluripotent Stem Cells

12:05 pm senomiRs® – circulating microRNA biomarkers for diagnosis of senescence burden and treatment response

12:15 pm Lunch & Networking

1:15 pm Induced Tissue Regeneration (iTR) using Natural and Engineered Extracellular Vesicles

1:40 pm Transient Reprogramming for Multifaceted Reversal of Aging Phenotypes

  • Jay Sarkar Co-Founder & CTO, Turn Biotechnologies

2:05 pm Impact of the FOXO3 Gene on Telomeres & Inflame-Aging

  • Rich Allsopp Professor, John A. Burns School of Medicine, University of Hawaii

2:30 pm Telomeres & Aging: Resetting Gene Expression

2:55 pm A Shortcut to Understanding Longevity

  • Steve Turner Senior Scientific Fellow and Interim Vice President of Development , InVivo Biosystems

Synopsis

• Introducing InVivo Biosystems Longevity Platform, an effective approach to
determine, in 3 months or less, a compound’s ability to extend lifespan and
healthspan.
• Conventional methods are limited in their ability to inform understanding of
mechanism of action.
• The precise model and deep phenotyping offered by the InVivo Biosystems
Longevity Platform addresses this challenge by producing high dimensional vitality
data as well as whole transcriptome sequence.
• We have succeeded in helping customers to demonstrate the value of novel
compounds in a matter of weeks.

3:05 pm Afternoon Refreshments & Networking

4:05 pm Buck Institute for Research on Aging Research Breakthroughs

Mapping Out The Longevity Biotechnology Landscape – Part 1

4:30 pm Chronic Disease through the Lens of Aging: Omics Studies of Healthy Aging Cohorts Reveal New Drug Targets In Multiple Therapeutic Areas

4:55 pm Longevity Therapeutics Research in Australia

  • Andrea Maier Divisional Director Medicine & Community Care & Professorial Fellow General Medicine & Aged Care, University of Melbourne

5:20 pm Antibody-mediated inhibition of the CD38 enzyme for the treatment of metabolic disorders

Synopsis

• Multivalent human heavy-chain anti-CD38 antibodies are potent inhibitors of
the CD38 hydrolase enzyme activity
• Inhibition of the CD38 enzyme activity leads to an immediate and sustained rise
of intracellular NAD+ and NMN in vivo and in vitro
• Inhibition of CD38 is strongly anti-inflammatory in animal models

5:50 pm Chair’s Closing Remarks

6:00 pm Poster Session